From Name:
From Email:
To Name:
To Email:

Optional Message:


Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion

from JAMA Oncology

In this randomized clinical trial of 247 patients, those receiving sorafenib plus hepatic arterial infusion chemotherapy had a significantly longer median overall survival time (13.37 vs 7.13 months) and acceptable safety profiles compared with patients receiving sorafenib. First-line sorafenib plus hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma and portal vein invasion improved survival compared with sorafenib alone. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063